Glenmark Pharmaceuticals has announced the launch of an inhaled dry powder fixed dose combination of indacaterol and mometasone furoate for the treatment of asthma which is being marketed under the name “Indamet”. All three of the strengths offered include 150 mcg of indacaterol, plus either 80, 160, or 320 mcg of mometasone.
Glenmark Group VP and Head, India Formulations, Alok Malik, commented, “Respiratory is a key focus area for Glenmark and the company leads from the front in providing access to the latest treatment options to patients. We are proud to introduce this novel fixed dose combination Indamet, which is the first of its kind in India; offering a world class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”
Read the Glenmark Pharmaceuticals press release.
